Abstract
Background Several reports suggest endothelial dysfunction and loss of endothelial barrier function in COVID-19. It is well established that the endothelial glycocalyx-degrading enzyme heparanase (HPSE) contributes to vascular leakage and inflammation. Low molecular weight heparins (LMWH) serve as an inhibitor of heparanase. We hypothesize that heparanase contributes to the pathogenesis of COVID-19, and that HPSE may be inhibited by the use of LMWH.
Methods Heparanase activity and heparan sulfate levels were measured in plasma of healthy controls (n=10) and COVID-19 patients (n=48).
Findings Heparanase activity and heparan sulfate levels were significantly elevated in plasma of COVID-19 patients. There was an association between heparanase activity and disease severity including the need for intensive care and mechanical ventilation, lactate dehydrogenase levels and creatinine levels. Use of prophylactic low molecular weight heparin in non-ICU patients was associated with a reduced HPSE activity.
Interpretation Prophylactic doses of low molecular weight heparin reduces heparanase activity in COVID-19. In addition to HPSE inhibition, low molecular weight heparin contributes to anti-coagulation and may exert anti-inflammatory effects. Since there is no other clinically applied heparanase inhibitor currently available, treatment of COVID-19 patients with low molecular weight heparins should be explored.
Funding This study was financially supported by the Radboudumc PhD fellow program, consortium grant LSHM16058-SGF (GLYCOTREAT; a collaborative project financed by the PPP allowance made available by Top Sector Life Sciences & Health to the Dutch Kidney Foundation to stimulate public-private partnerships), ERC Advanced grant (#833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research.
Evidence before this study Severe forms of COVID-19 present with acute respiratory disease syndrome (ARDS) and proteinuria, which are both associated with a leaky vasculature. An increased activity of the endothelial glycocalyx degrading enzyme heparanase (HPSE) compromises endothelial barrier function. HPSE activity-mediated loss of endothelial barrier function has been established for several inflammatory disease conditions including infection/sepsis, ARDS and proteinuric kidney diseases.
Added value of this study This study demonstrates that HPSE activity is increased in COVID-19 patients, especially in those with severe disease like ICU patients. Additionally, use of prophylactic doses of low molecular weight heparin (LMWH) is associated with a reduced heparanase activity in COVID-19 patients.
Implications of all the available evidence Increased HPSE activity in COVID-19 contributes to vascular leakage as manifested by ARDS and proteinuria. LMWH inhibits HPSE activity, contributes to anti-coagulation and exerts anti-inflammatory effects. Since LMWH is the only clinically approved HPSE inhibitor, treatment of COVID-19 patients with therapeutic doses of LMWH should be explored.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study was performed according to the latest version of the declaration of Helsinki and guidelines for good clinical practice. The local independent ethical committee approved the study protocol (CMO 2020-6344, CMO 2020-6359, CMO 2016-2923).
Funding Statement
This study was financially supported by the Radboud university medical center PhD fellow program and consortium grant LSHM16058-SGF (GLYCOTREAT; a collaborative project financed by the PPP allowance made available by Top Sector Life Sciences & Health to the Dutch Kidney Foundation to stimulate public-private partnerships) coordinated by JvdV. MGN was supported by an ERC Advanced grant (#833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed according to the latest version of the declaration of Helsinki and guidelines for good clinical practice. The local independent ethical committee approved the study protocol (CMO 2020-6344, CMO 2020-6359, CMO 2016-2923).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Johan van der Vlag has full access to all the data in the study and takes responsibility for the integrity of the data. All data are available in the manuscript.
